MaxCyte Partners with Curamys to Advance Cell and Gene Therapies for Rare Diseases: A Strategic Platform License Agreement
MaxCyte Signs Strategic Platform License with Curamys to Enable Advancements in Cell Fusion Technology ROCKVILLE, Md. and SEOUL, South Korea, Dec. 04, 2022 (GLOBE NEWSWIRE) — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics… MaxCyte, Inc., a…